- NUF Congress 2015

NUF Congress
3 - 5 June 2015
Programme Book
30 th
Congress
Anniversary
Tweet at #NUF2015
Visit www.nuf2015.se for
facebook.com/nuf2015
programme & informaon
on your mobile device!
Malmö Arena
NUF Congress, 3-5 June 2015
WIFI. Net: MalmöArenaGuest
Poster Area
Exhibition
Plan A
Arenarummet
Registration
Entrance
A1
A20
Wardrobe
Stairs to NP
NP
(Nedre Plan)
Palissad Väst
Speakers service
center
Palissad Öst
Palissad Syd
Stairs from Plan A
2015.04.26
©Destination Öresund
Dear colleagues, nurses, attendees and sponsors!
Our Association has a long tradition to have a congress every second year. This
time the 30th NUF Congress will be in Malmö. So this is a special anniversary
meeting! The organizing committee in Malmö has done a superb work. I warmly thank Prof. Per-Anders Abrahamsson, Dr. Saeed Dabestani and the whole
committee for their efforts! I also warmly thank our sponsors for their support.
The economical situation and the regulations make supporting more difficult,
but it is still important.
For the second time there will be a separate session for the Nordic Residents in
Urology. The topic is non-muscle invasive bladder cancer. During the following
days we will have top-level scientific sessions, lively discussions and hopefully an
enjoyable congress.
Scandinavian Association of Urology is an umbrella organization and the
main function is to support the collaboration working groups. During the Presidium Meeting and General Assembly we will hear the reports of the groups
and all other activities.
I hope we will have a fruitful congress with lively discussions.
With best wishes to all Nuffare and welcome to Malmö!
Kimmo Taari
President NUF
Time 09.00 – 12.00 NUF Congress 2015 – Scien=fic Programme Wednesday 3rd of June 09.00 – 14.00 Parallel Session 1 Room: Palissad VÄST Parallel Session 2 Room: Arenarummet Nurses Programme Room: Palissad ÖST Residents’ Day Programme: Non-­‐muscle invasive Bladder Cancer (con=nued) (NB! See separate programme Ime table and locaIon) Registra=on 11.00 – 12.00 10.00 -­‐13.00 Registra=on at Malmö Arena SPCG symposium 11.00 SPCG – Research Grant 2013 and 2014 G Ahlgren (Sweden) 11.20 SPCG – S=ll alive and ac=ve G Ahlgren (Sweden) 11.40 SPCG 15 – The next landmark study has started O Akre (Sweden) 12.00 – 13.00 13.00 – 13.10 LUNCH and exhibi=on Welcome PA Abrahamsson (Sweden) / K Taari (Finland) Room: Arenarummet 13.10 – 14.00 State-­‐of-­‐the-­‐Art: Infec=on control – How do we avoid a future disaster? Prof. Inga Odenholt Room: Arenarummet PlaInum Sponsor 4
NUF Congress 2015 – Scien=fic Programme Wednesday 3rd of June 14.00 – 19.00 Time 14.00 – 15.00 Parallel Session 1 Room: Palissad VÄST Parallel Session 2 Room: Arenarummet Nurses Programme Room: Palissad ÖST Bladder Cancer research – are molecular markers ready for clinical use? Localized Prostate Cancer – Primary treatment or not? Chair: A Bjartell (Sweden) Chair: E Grainer (Denmark) Chair: P Boström (Finland) 14.00 A clinicians perspec=ve J Bjerregaard Jensen (Denmark) 14.00 Ac=ve Surveillance – When and how? A Rannikko (Finland) 14.15 Urinary markers for diagnosis and surveillance EC Zwarthoff (Netherlands) 14.35 Which are the most promising and best validated molecular prognos=c markers in Bladder Cancer today? L Dyrskjot (Denmark) 14.20 Radical Prostatectomy – Why and for whom? J Hugosson (Sweden) 14.40 Focal therapy – Is it an op=on? M Emberton (United Kingdom) 15.00 – 15.45 15.45 – 16.30 The LEAN Bladder Cancer team – a mul=disciplinary approach. Chair: Fredrik Liedberg (Sweden) 15.45 Iden=fying clinical errors in daily prac=ce F Liedberg (Sweden) 15.55 The LEAN Bladder Cancer Team J Wanegård/AK Lind (Sweden) 16.10 The primary TURB – an important task A Sörenby (Sweden) Break and exhibi=on Localized Prostate Cancer – Side effects and QoL Chair: G Ahlgren (Sweden) & K Tari (Finland) 15.45 ED & Side effects from treatment – an overview E Johansson (Sweden) 16.00 Cases and discussions Speakers act as panel Urinary Drainage 14.00 Nephrostomy catheters R Knudsen (Denmark) 14.20 To educate pa=ents in Clean Intermi.ent Catheteriza=on M Lauritzen (Sweden) 14.40 Special urinary catheters E Broström (Sweden) Sponsored NUF Debate mee=ng Moderator: Journalist MarXn Krasnik, (Denmark) 15.45 How will the Nordic healthcare systems handle the increased pressure caused by an ageing popula=on? Panel: Mef Nilbert (Sweden) Jes Søgaard (Denmark) Stefan Lamme (Sweden) Ola BraR (Sweden) NB! For all par=cipants! See page 10 for details 16.30 – 17.30 Oral Presenta=on #1 Chairs: M Tinzl (Sweden) & K Hovgaard Andreassen (Denmark) Urolithiasis and Urological Infec=on Abstract Number #01 – #07 See page 9 for details 17.30 – 19.00 Sponsored Symposium 17.30 – 19.00. mCRPC – Janssen See page 9 for details 19.00 – Oral Presenta=on #2 Chairs: O Akre (Sweden) & H BerXlsson (Norway) Localized Prostate Cancer, Early Detec=on, Epidemiology and Imaging Abstract Number #08 – #16 See page 9 for details Contact Nurses Chair: R Knudsen (Denmark) 16.30 Contact nurses for pa=ents with Penile Cancer K Jacobsson (Sweden) A Trent (Sweden) 17.00 Contact nurses for pa=ents with Kidney Cancer G Carlsen (Norway) M Loeng (Norway) Sponsored Symposium 17.30 – 19.00. Bladder Dysfunc=on – Astellas See page 11 for details Official opening of the NUF Congress Room: Arenarummet Get together party held at Malmö Arena. (See page 14 for details) 5
NUF Congress 2015 – Scien=fic Programme Thursday 4th of June 08.00 – 13.15 Parallel Session 1 Room: Palissad VÄST Time 08.00 – 09.30 Renal Cell Carcinoma (RCC) Parallel Session 2 & Nurses Programme Room: Arenarummet Trends in trea=ng LUTD – An update Chairs: B Ljungberg (Sweden) & P Elfving (Sweden) 08.00 Introduc=on B Ljungberg (Sweden) Chair: E Farrelly (Sweden) 08.00 Trends in pharmacological treatment K-­‐E Andersson (Denmark) 08.05 Tumor biopsy and ac=ve monitoring of Renal Tumors A Volpe (Italy) 08.30 Pelvic floor exercise, Bladder retraining J Sjögren (Sweden) 08.25 Renal Tumor Scoring Systems H Nisén (Finland) 08.45 Botox L Malmberg (Sweden) 08.40 RF-­‐treatment of Renal Tumors V Acosta (Sweden) 09.00 Tibial and Vibratory Nerve S=mula=on M Fode (Denmark) 08.55 Danish Na=onal Cancer Pathways B Kromann (Denmark) 09.15 Sacral Neuromodula=on M Aho (Finland) 09.15 Na=onal Swedish Kidney Cancer Register B Ljungberg (Sweden) 09. 30 – 10.15 Break and exhibi=on 10.15 – 12.15 Penile and Tes=cular Cancer Trends in trea=ng LUTD – An update (con=nued) Chair: J Jacobsen (Denmark) 10.15 Introduc=on J Jacobsen (Denmark) Chairs: M Aho (Finland) & K Hjelle (Norway) 10.20 The Swedish Na=onal Penile Cancer Register data P Kirrander (Sweden) 10.45 Organ-­‐sparing Reconstruc=ve Surgery in Penile Cancer U Håkansson (Sweden) 11.05 PenCaBaSe -­‐ Penile cancer research database Sweden P Kirrander (Sweden) 11.25 SCAPECA -­‐ Nordic Collabora=ve Group on Penile Cancer J Jacobsen (Denmark) 10.15 Treatment of male incon=nence H Veiby Holm (Norway) 10.45 Interdisciplinary teamwork – Experiences from different countries •  A Jacobsen, A Debes, C Teig Akershus (Norway) •  C Graugaard Århus (Denmark) •  P Teleman Malmö (Sweden) 12.15 – 13.15 6
11.45 Retroperitoneal lymph node dissec=on in Tes=cular Cancer U Håkansson (Sweden) LUNCH and exhibi=on NUF Congress 2015 – Scien=fic Programme Thursday 4th of June 13.15 – 19.00 Time 13.15 – 14.00 Parallel Session 1 Room: Palissad VÄST Parallel Session 2 Room: Arenarummet Nurses Programme Room: Palissad ÖST Pa=ent reported outcome measures in surgical care Prof. Ewa Idvall (Sweden) State-­‐of-­‐the-­‐Art: Ethics in decision making 14.00 – 15.00 Oral Presenta=on #3
Chairs: A Ranniko (Finland) & J Stranne (Sweden) Localized Prostate Cancer Treatment Abstract number #17 – #26 See page 10 for details Prof Ingrid Bolmsjö (Sweden) Room: Arenarummet Urolithiasis & Endourology Female and male sexuality Chairs: M Brehmer (Denmark) & aser urological surgery
A Mikkola (Finland) 14.00 Is SWL gepng old fashion? HG Tiselius (Sweden) 14.15 Is “mini-­‐perc” be.er than standard PCNL? M Tinzl/S Nilsson (Sweden) Chair: E Grainer (Denmark) 14.00 Female and male sexuality aser urological surgery B Kiesbye (Denmark) 14.30 Tips and Tricks in flexible kidney stone management O Traxer (France) 15.00 – 15.30 15.30 – 16.45 Break and exhibi=on Oral Presenta=on #4
Chairs: L Salling (Denmark) & A Rannikko(Finland) Renal/Penile Cancer & Reconstruc=ve Surgery Abstract Number #27 – #36 See page 10 for details Urolithiasis & Endourology 15.30 Kidney stone in children P Osther (Denmark) 15.45 Obstruc=on and Stone management during pregnancy – an algorithm Ø Ulvik (Norway) Oral Presenta=on #5 Chairs: K Stenzelius (Sweden) & O Patschan (Sweden) BPH, LUTD & Andrology Abstract number #37 – #44 See page 11 for details 15.55 Assessment, evalua=on of stone formers and medical assessment K Hovgaard Andreassen (Denmark) 16.25 Take home message – by Chairs 16.45 – 18.00 NUF General Assembly See page 14 for details 19.00 – Sponsored Symposium 16.45 – 18.00. mCRPC – Astellas See page 13 for details Congress Dinner (see page 14 for details) Venue: Glasklart, Expected arrival at 19.00! Address: Dockplatsen 1, 211 19 Malmö, Sweden 7
NUF Congress 2015 – Scien=fic Programme Time 08.00 – 09.30 Friday 5th of June 08.00 – 12.10 Parallel Session 1 Room: Palissad VÄST Parallel Session 2 Room: Arenarummet Oral Presenta=on #6 Prostate Cancer – Salvage Treatment Chairs: S Guðjonsson (Sweden) & G Wrist Lam (Denmark) Urothelial Cancer Abstract Number #45 – #54 Chair: JE Damber (Sweden) 08.00 Salvage prostatectomy – When and for whom?
C SXef (Germany) 08.20 Salvage Cryotherapy – Is it an op=on? G Ahlgren (Sweden) 08.40 Salvage HDR Brachytherapy W Lilleby (Norway) 09.00 Cases and discussion JE Damber (Sweden) 09.30 – 10.15 10.15 – 11.20 Oral Presenta=on #7 Chairs: A Bjartell (Sweden) & M Fode (Denmark) Prostate Cancer (various) Abstract number #55 – #64 11.20 – 11.50 Nurses Programme Room: Palissad ÖST Oral Presenta=on #A Chairs: R Knudsen (Denmark) & A Khatami (Sweden) Nurses Programme Abstracts Number #A1 – #A4 09.20 European Associa=on of Urology Nurses (EAUN) –
Informa=on E Grainer (Denmark) Break and exhibi=on Oral Presenta=on #8 Chairs: A Rannikko(Finland) & L Lund (Denmark) Prostate Cancer (various) Abstract number #65 – #74 How to meet pa=ents and rela=ves in crisis Chair: K Stenzelius (Sweden) 10.15 How to meet pa=ent and rela=ves in crisis N Cavalli Björkman (Sweden) State-­‐of-­‐the-­‐Art: Urological Diseases in a Global Perspec=ve Ass. Prof. Magnus Grabe (Sweden) Room: Arenarummet 11.50 – 12.10 Awards and Closing Remarks PA Abrahamsson (Sweden) / L Salling (Denmark) Room: Arenarummet Gold Sponsor 8
Oral Presenta=ons Wednesday 3rd June – 16.30 – 17.30 Abstract # Room #01 #02 #03 #04 #06 #07 #09 #10 #11 #12 Time slot Presenter Title 16.36 -­‐ 16.42 Oral Presenta=on #1 16.42 -­‐ 16.48 Urolithiasis and 16.48 -­‐ 16.54 Urological Infec=on 16.54 -­‐ 17.00 Palissad 16.30 -­‐ 17.30 VÄST #05 #08 Session # & Time Chris=ansen Does the internal structure of renal calculi on NCCT predict ESWL outcome? Rigid paIent selecIon for tubeless PCNL may not be warranted -­‐ Fuglsig The Aarhus experience. Acquired male urethra diverIculum with lithiasis presenIng as a Gaspar penile mass Jakobsen AK Spectrum and incidence of definiIve surgery for Nephrolithiasis in Ankylosing SpondyliIs and general populaIon: a prospecIve populaIon-­‐based Swedish naIonal cohort study with matched general populaIon comparator subjects 17.00 -­‐ 17.06 Wieborg von Topiramate-­‐induced nephrolithiasis Rosen AnIbioIc prophylaxis for prostate biopsies – A prospecIve, 17.06 -­‐ 17.12 Mygland randomized study of trimethoprim sulfamethoxazole vs. ciprofloxacin A case of fulminant emphysematous pyelonephriIs 17.12 -­‐ 17.18 Nilsson S 16.36 -­‐ 16.42 Oral Presenta=on #2 16.42 -­‐ 16.48 Localized Prostate Cancer, 16.48 -­‐ 16.54 Early Detec=on, Epidemiology and Imaging 16.54 -­‐ 17.00 Arena-­‐
16.30 -­‐ 17.30 17.00 -­‐ 17.06 rummet #13 #14 #15 #16 Røder MA ERG protein expression over Ime -­‐ from diagnosIc biopsies to radical prostatectomy specimens in clinically localized prostate cancer Thomsen FB Risk of malignant melanoma in men with prostate cancer, naIonwide populaIon-­‐based study A randomized controlled trial to assess and compare the outcomes Baco of 2-­‐core MRI/TRUS-­‐image-­‐fusion guided prostate biopsy and tradiIonal 12-­‐core systemaIc biopsy DiagnosIc potenIal of 18F-­‐FACBC PET/MRI in high risk prostate Ber=lsson cancer Prostate Cancer: MulI-­‐Parametric MagneIc Resonance Imaging of Elkjaer the Prostate reclassifies paIents eligible for AcIve Surveillance Performance characterisIcs of mulIparametric magneIc 17.06 -­‐ 17.12 Kohestani resonance imaging (mpMRI) prior to radical prostatectomy – which prostate cancers are missed? 17.12 -­‐ 17.18 Helgstrand JT DaPCaR – The Danish Prostate Cancer Registry. A new comprehensive database of men evaluated for prostate cancer in 1995-­‐2011 Local insights into the naIonal detecIon of Prostate Cancer 17.18 -­‐ 17.24 Dyal The effect of socioeconomic status in the Finnish Prostate Cancer 17.24 -­‐ 17.30 Taari Screening Trial JANSSEN ORGANIZED SYMPOSIUM Time: Wednesday 3rd June 2015 17.30 – 19.00 Room: Palissad VÄST Individualized treatment in metasta=c Castra=on Resistant Prostate Cancer Scien=fic Commi.ee
Göran Ahlgren (Sweden) and Jon Reidar Iversen (Norway) Faculty Antonio Alcaraz (Spain) and Heather Payne (United Kingdom) Programme: 17.30-­‐17.35
Welcome and introduc=on Göran Ahlgren 17.35-­‐17.55 Systemic treatment considera=ons in mCRPC -­‐ which treatment, to whom and when? Jon Reidar Iversen 17.55-­‐18.15 Management of pa=ents with comorbidi=es Antonio Alcaraz 18.15-­‐18.35
How to maximize Quality of Life in the care of mCRPC pa=ents Heather Payne 18.35-­‐18.55
Panel discussion All 18.55-­‐19.00
Closing remarks Göran Ahlgren 9
Oral Presenta=ons Thursday 4th June – 14.00 – 16.45 Abstract # Room Time slot Presenter Title 14.00 -­‐ 14.06 Oral Presenta=on #3 Localized 14.06 -­‐ 14.12 Prostate Cancer 14.12 -­‐ 14.18 Treatment 14.18 -­‐ 14.24 14.00 -­‐ 15.00 #17 #18 #19 #20 #21 Session # & Time Palissad VÄST Thomsen FB Tikkinen Fode Frey 14.24 -­‐ 14.30 Jacobsen A 14.30 -­‐ 14.36 Oddason #22 14.36 -­‐ 14.42 Røder MA #23 14.42 -­‐ 14.48 Thomsen FB #24 14.48 -­‐ 14.54 Koch #25 14.54 -­‐ 15.00 Røder MA #26 #27 #28 #29 #30 #31 #32 #33 #34 #35 Palissad VÄST 15.36 -­‐ 15.42 Oral Presenta=on #4 15.42 -­‐ 15.48 Renal/Penile 15.48 -­‐ 15.54 Cancer & Reconstruc=ve 15.54 -­‐ 16.00 Surgery 16.00 -­‐ 16.06 15.30 -­‐ 16.45 Hjelle Mariusdopr Fagerström Liedberg Mar=ns FE 16.06 -­‐ 16.12 Mar=ns FE 16.12 -­‐ 16.18 Warner 16.18 -­‐ 16.24 Ellertsson-­‐
Csillag 16.24 -­‐ 16.30 Jakobsen JK 16.30 -­‐ 16.36 Trelborg #36 PrognosIc value of PSA kineIcs in paIents with localised prostate cancer managed observaIonally: a sub-­‐group analysis of the SPCG-­‐6 study SystemaIc review and meta-­‐analysis of decision aids for localised prostate cancer treatment choice PaIent saIsfacIon aper radical prostatectomy: The influence of oncological and funcIonal outcomes The single quesIon approach is a robust alternaIve to the internaIonal index of erecIle funcIon erecIle funcIon domain when evaluaIng post radical prostatectomy erecIle dysfuncIon AnastomoIc complicaIons aper radical prostatectomy – a comparison of open and robot assisted procedures Brachy therapy for prostate cancer in Iceland, primary results Risk of biochemical recurrence aper radical prostatectomy for prostate cancer -­‐ Updated analysis of the Rigshospitalet cohort The impact of the Movember campaign on referral paRerns, diagnosis and treatment of prostate cancer Focal One® – More than simple HIFU Heterogeneity of D’Amico intermediate-­‐risk prostate cancer – an analysis of biochemical recurrence aper radical prostatectomy at Rigshospitalet. Surgical Treatment of Localized Renal Cell Carcinoma (RCC) in Norway 2008 -­‐2012. Risk factors for renal cell cancer in Iceland– a naIon-­‐wide, prospecIve epidemiological study ProphylacIc mesh placement for prevenIng parastomal hernias in paIents receiving a Bricker ileal conduit Long-­‐term outcome aper conInent cutaneous diversion a.m. Lundiana in 198 paIents Urethral reconstrucIon following arIfical urinary sphincter cuff infecIon-­‐erosion Management of iatrogenic urorectal fistulae in pelvic cancer A mulI-­‐insItuIonal evaluaIon of the management and outcomes of long-­‐segment urethral strictures Penis cancer in Iceland 1989-­‐2014. Incidence and survival. UnintenIonal weight loss but not obesity predicts cancer-­‐
specific survival in paIents with invasive penile cancer Laparoscopic cryoablaIon of angiomyolipomas in adolescents and young adults: a report of 4 cases associated with tuberous sclerosis and 1 case of sporadic origin. Sponsored NUF Debate mee=ng Time: Wednesday 3rd June 15:45–16:30 For all parIcipants. Room: Palissad ÖST How will the Nordic health care systems handle the increased pressure caused by an ageing popula=on? – Focus on prostate cancer – the fastest growing cancer form in the Nordics. A panel debate with key poliIcal and scienIfic stakeholders discussing the challenges and opportuniIes we are currently facing. Moderator: MarIn Krasnik, Danish journalist, author and TV-­‐host known for his interviews on the popular news programme Deadline. Panel: •  Mef Nilbert, Leader of Regional Cancer Center South, Sweden. •  Jes Søgaard, Health Economist, Kræpens Bekæmpelse, Denmark. •  Stefan Lamme, ConservaIve party and the leading opposiIon within Health maRers in the Region of Skåne, Sweden. •  Ola BraR, M.D., Ph.D., F.E.B.U. Associate Professor of Urology, Lund and Consultant Urological Surgeon, Cambridge. Sweden 10
Oral Presenta=ons Thursday 4th June – 15.30 – 16.45 (conInued) Abstract # Room Session & Time Time slot Presenter Title #37 #38 #39 #41 #42 Oral Presenta=on #5 BPH, LUTD & Andrology Palissad 15.30 -­‐ 16.45 ÖST 15.36 -­‐ 15.42 Patschan O HOLEP during the learning curve versus open prostatectomy 15.42 -­‐ 15.48 Pesonen The impact of nocturia on mortality: a systemaIc review and meta-­‐analysis Preparing for blood transfusion with BAS-­‐test prior to TUR-­‐P surgery UIlity and reliability of test vials in cryopreservaIon of human semen MulIple needle-­‐pass percutaneous tesIcular sperm aspiraIon as first-­‐line treatment in azoospermic men Poluorchidism – a case presentaIon and a review 15.48 -­‐ 15.54 Sjöström 15.54 -­‐ 16.00 Jensen C 16.00 -­‐ 16.06 Jensen C 16.06 -­‐ 16.12 Padkaer #43 16.12 -­‐ 16.18 Borisdopr #44 Sexuality in women undergoing cystectomy: Is there need for improvement in the informaIon given to paIents pre-­‐ and postoperaIvely? Astellas Sponsored Symposium The Ageing Bladder and bladder dysfunc=on Past – Present – Future Time: Wednesday 3rd June 17:30–19:00 Room: Arenarummet Moderator: Lars Malmberg MD, PhD Skåne University Hospital Speakers: •  Marh Aho MD, PhD. Tampere University Hospital • 
Prof Karl-­‐Erik Andersson, Aarhus University Hospital/ Wake Forest Univ. School of Med. • 
Charloie Graugaard-­‐Jensen MD, PhD. Aarhus University Hospital. 11
Oral Presenta=ons Friday 5th June – 8.00 – 11.20 NB! If you are presen=ng in the 08.00 – 09.30 poster session make sure to upload your presenta=on the day before Abstract # Room Session & Time slot Presenter Title Time 08.06 -­‐ 08.12 Oral Presenta=on #6 08.12 -­‐ 08.18 Urothelial Cancer 08.18 -­‐ 08.24 08.00 -­‐ 09.30 08.24 -­‐ 08.30 #45 #46 #47 Björnsson Radical cystectomy in the treatment of bladder cancer in Iceland: A populaIon based study Blindheim The PCNA targeIng pepIde drug ATX-­‐101 enhances the efficacy of intravenous chemotherapy for muscle-­‐invasive bladder cancer. Accuracy on visual staging of bladder cancer during endoscopic procedures Gaspar Lam 08.36 -­‐ 08.42 Jensen TK Robot assisted radical cystectomy (RARCx) and intracorporal urinary diversion as standard cystectomy procedure – 5 year follow up on oncological results in 225 consecuIve paIents. Comparison of the prognosIc and predicIve value of the biomarkers emmprin, survivin and ki67 in paIents enrolled in two randomized studies of cystectomy with or without neoadjuvant chemotherapy Invasive bladder cancer in elderly in Denmark, 2008-­‐2012 08.42 -­‐ 08.48 Nilsen F Maintenance BCG over 30 months in NMIBC paIents. 08.54 -­‐ 09.00 Patschan O Large regional differences in the applicaIon of second-­‐look resecIon in stage T1 bladder cancer in Sweden 09.00 -­‐ 09.06 Poulsen A Early and late complicaIons aper cystectomy, trends over Ime. 09.06 -­‐ 09.12 Nassir High grade T1 bladder urothelial carcinoma: OpImal management. #48 08.30 -­‐ 08.36 Hemdan #49 Palissad VÄST #50 #51 #52 #53 #54 10.18 -­‐ 10.24 Oral Presenta=on #7 10.24 -­‐ 10.30 Prostate 10.30 -­‐ 10.36 Cancer (various) 10.36 -­‐ 10.42 10.15 -­‐ 11.20 #55 #56 #57 #58 #59 #60 #61 #62 Palissad VÄST Poulsen MH PredicIng Prostate Biopsy Results Using a Panel of Plasma and Urine Biomarkers Combined in a Scoring System Canesin TargeIng Wnt5a and STAT3 pathways for the treatment of prostate cancer. Don-­‐Doncow Expression of pSTAT3 in hormone-­‐naïve and castrate-­‐resistant prostate cancer Josefsson CirculaIng tumour cells as treatment predicIve biomarker for androgen deprivaIon therapy in hormone naïve prostate cancer Urokinase plasminogen acIvator receptor (uPAR) assessment 10.42 -­‐ 10.48 Røder MA in localized-­‐, hormone naïve-­‐, and castraIon resistant prostate cancer The predicIve value of ERG protein expression for 10.48 -­‐ 10.54 Røder MA development of castraIon-­‐resistant prostate cancer – assessment of hormone-­‐naïve advanced prostate cancer paIents treated with primary androgen deprivaIon therapy. 10.54 -­‐ 11.00 Krzyzanowska QuanItaIve Time Resolved Fluorescence Imaging of Androgen Receptor and Prostate Specific AnIgen in Prostate Tissue SecIons TesIcular metastasis from prostate cancer. A review of the 11.00 -­‐ 11.06 Geertsen literature 11.06 -­‐ 11.12 Anand #63 #64 12
QuanItaIve Imaging by Automated Bone Scan Index (BSI) as a Response Biomarker in Standard Clinical Care of PaIents with metastaIc castraIon resistant Prostate Cancer (mCRPC) Treated with Enzalutamide 11.12 -­‐ 11.18 Helgstrand JT PSA nadir and Ime to PSA nadir as prognosIc markers for development of castraIon-­‐resistant prostate cancer upon treatment with 1st line androgen deprivaIon therapy Oral Presenta=ons Friday 5th June – 8.00 – 11.20 (conInued) NB! If you are presen=ng in the 08.00 – 09.30 poster session make sure to upload your presenta=on the day before Abstract # Room #A1 #A2 #A3 Palissad ÖST #A4 #65 #66 #67 #70 Abstract 08.20 -­‐ 08.30 Ragle Presenta=on #A 08.35 -­‐ 08.45 Norling Nurses Programme 08.50 -­‐ 09.00 Sjögren 08.00 -­‐ 09.30 09.05 -­‐ 09.15 Saavedra Group based exercise with transiIon to out of hospital training. 10.18 -­‐ 10.24 Abrahamsson Oral Presenta=on #8 10.24 -­‐ 10.30 Borre Prostate Cancer (various) 10.30 -­‐ 10.36 Nielsen TK 10.15 -­‐ 11.20 Factors predicIng the off-­‐treatment duraIon during intermiRent androgen deprivaIon (IAD) therapy with degarelix in prostate cancer ProspecIve observaIonal assessment of the effecIveness of Enzalutamide treatment in paIents with MetastaIc castraIon-­‐
resIstant prostate cancer in a real-­‐world clinical pracIce seyng: protocol of the ongoing PREMISE study High-­‐dose ascorbic acid in metastaIc castraIon-­‐resistant prostate cancer: evaluaIon of efficacy and safety in a phase II trial Androgen DeprivaIon Therapy: Is orchiectomy the paIent’s choice? 10.36 -­‐ 10.42 Østergren #68 #69 Session & Time slot Presenter Title Time Arena-­‐
rummet 10.42 -­‐ 10.48 Thomsen FB 10.48 -­‐ 10.54 Wolf 10.54 -­‐ 11.00 Bosnyak #71 11.00 -­‐ 11.06 Nolvi #72 #73 #74 11.06 -­‐ 11.12 Rüssel 11.12 -­‐ 11.18 Ladjevardi Student experience of school toilets Urinary symptoms and toileIng behaviour among younger women. Quality of care aper TUR-­‐P in southern Sweden Bicalutamide 150 mg daily vs. Placebo in hormone-­‐naïve, non-­‐
metastaIc prostate cancer paIents: long-­‐term survival update of the Scandinavian Prostate Cancer Group 6 study Surveillance of adverse events of Abiraterone using Skype remote consultaIons DifferenIal effects of medical androgen deprivaIon therapies on serum alkaline phosphatase levels in men with prostate cancer Hospital district budget impact analysis of degarelix in the treatment of men with prostate cancer and history of cardiovascular event in Finland Androgen deprivaIon therapy (ADT) and cardiovascular (CV) risk – analysis of German Statutory Health Insurance (SHI) data Fusion-­‐guided prostate biopsy with mulIparametric MRI and TRUS, early experience Astellas Sponsored Symposium Possibili=es and challenges with the new treatments within mCRPC Time: Thursday 4th June 16:45–18:00 Room: Arenarummet Moderator: Prof Peter Iversen Speakers: •  Prof Karim Fizazi – PossibiliIes and challenges with the new treatments available for mCRPC. An update on sequencing, resistance and a brief overview on the recent development of biomarkers • 
Prof Jan Erik Damber – ImplementaIon of new treatment modaliIes – A Nordic overview. 13
Social Programme – Details Tuesday 2nd June 19.15 The Residents' Dinner will be held at Mötesplats CRC near the Residents' Day lecture hall. The address is Jan Waldenströms gata 35, Malmö. The residents aRending will be led in group to the venue aper the evening lectures. Wednesday 3rd June 19.00 Get together party will be held at Malmö Arena aper the Official opening of the NUF Congress. Room: Arenarummet & ExhibiIon hall Thursday 4th June 19.00 Congress Dinner will be held at "Glasklart" found in Malmö's Western Harbor area. The address is Dockplatsen 1, 211 19 Malmö. Please be on Ime! Gepng to the Congress Dinner Venue (Glasklart) • 
Grabbing a taxi is the most convenient opIon and should cost between 60 and 110 SEK. • 
Bus travel to the venue is via green bus number 5 towards “Västra Hamnen" from Malmö Central staIon. Get off at the “Dockan” stop. • 
Walking from Malmö C to the venue takes is around 15 minutes Map to Glasklart QR Code Malmö City bus lines QR Code Congress Dinner Entertainment: The entertainment for the evening will be none other than The Department of Urology House band “Dr D.R.E.” who will be performing for you throughout the dinner! The evening aperwards will conInue with music and dancing late into the night! Scandinavian Associa=on of Urology General Assembly Call for Scandinavian AssociaIon of Urology General Assembly meeIng at the NUF Congress 2015 Time: Thursday 4th June 16:30 – 17:30 Room: Palissad VÄST AGENDA: 1.  Protocol from General Assembly held in SandeÄord at NUF 2013 (available on www.nuf.nu). 2.  Report from the Board by the President 3.  Report from the Treasurer 4.  Report from Chief Editor of Scandinavian Journal of Urology. (available on www.nuf.nu). 5.  Report from the editors of the BulleIn 6.  Report from the editor of the NUF website 7.  Reports from the NUF CollaboraIon Groups ( available on www.nuf.nu) 8.  RelaIon to other organizaIons 9.  ElecIon 10.  Congress report by the President of NUF Congress 2015, Per-­‐Anders Abrahamsson 11.  Next Congress Odense, Denmark 2017 12.  Other subjects Lisbeth N. Salling General secretary, NUF 14
BET-142040-ND 04.2015 RELEVANS.NET
UroLog is a
free app from
Astellas Pharma.
Download it from
the App Store or
Google Play.
UroLogApp.se
UroLogApp.fi
UroLogApp.no
UroLogApp.dk
NEW!
OAB/LUTS APP
FOR YOU AND
YOUR PATIENTS
Astellas Pharma a/s | Kajakvej 2 | 2770 Kastrup Denmark | Phone +45 4343 0355 | Fax +45 4343 2224
kontakt.dk@astellas.com | www.astellas.dk | www.astellas.se | www.astellas.no | www.astellas.fi
Practicalities
Free travel with Skånetrafiken!
Your name tag to the Congress is valid
as ticket 3rd to 5th May 2015 at Skånetrafikens city buses and trains in Malmo
(Zone 250). Show it for bus drivers and
controllers.
Train - City Tunnel
From Malmö Central Station via the
Triangeln, trains run throughout the
day to station Hyllie / Malmo Arena by
Oresund trains, which then continue to
the Copenhagen Airport and Copenhagen. You can also take the purple Pågatågen to Hyllie / Malmo Arena which
go on to Ystad and Simrishamn.
City bus
City bus No. 6 runs from the Triangeln
to Hyllie / Malmö Arena via Borgmästargården (Mercure Hotel). City bus
No. 8 runs from Gustav Adolfs Torg
and further out to Hyllie / Malmö
Arena. Timetable and stops can be
found on www.skanetrafiken.se.
16
Taxi
You can also share a taxi with your
colleagues and get to Malmö Arena.
• Taxi Skåne: +46 (0) 40-330330
• Taxi 97: +46 (0) 40-97 97 97
Wifi
Locate network Malmö Arena Guest
and connect. No further login.
Contact Registration Desk
Destination Öresund,
+46 (0) 40 300 665
ACHIEVING
• 4.4 months increased median overall survival
• 10 months delayed time to opiate use
• Over 4 years of proven and consistent safety data
Prescribe ZYTIGA® as first line treatment and give your
mCRPC patients more time & better quality of life
mCRPC = Metastaserad kastrationsresistent prostatacancer
Referenser: 1. ZYTIGA® produktresumé 11/2014.
Janssen-Cilag AB Box 7073, SE-192 07 Sollentuna, Sweden, Tel +46 8 626 50 00, Fax +46 8 626 51 00, www.janssen.se
Time for life
JC-140461-3
Detta läkemedel är föremål för utökad övervakning. Detta kommer att göra det möjligt att snabbt identifiera ny säkerhetsinformation. Hälso- och sjukvårdspersonal uppmanas att rapportera varje misstänkt biverkning.
Tablett: ZYTIGA 250 mg tabletter. Vita till benvita, ovala tabletter, präglade med AA250 på en sida. Varje tablett innehåller 250 mg
abirateronacetat. Den rekommenderade dosen är 1000 mg (fyra tabletter på 250 mg) dagligen som en engångsdos, som inte får
tas tillsammans med mat. ZYTIGA ska användas tillsammans med lågdos prednison eller prednisolon. Den rekommenderade dosen
av prednison eller prednisolon är 10 mg dagligen. ATC-kod: L02BX03 Receptbelagt. Ej Förmån. Indikation: ZYTIGA är tillsammans
med prednison eller prednisolon indicerat för: • behandling av metastaserad kastrationsresistent prostatacancer hos vuxna män
som är asymtomatiska eller har milda symtom efter svikt av androgen deprivationsterapi hos vilka kemoterapi ännu inte är indicerad
• behandling av metastaserad kastrationsresistent prostatacancer hos vuxna män vars sjukdom har progredierat under eller efter
en docetaxelbaserad kemoterapiregim Trafikvarning: ZYTIGA har ingen eller försumbar effekt på förmågan att framföra fordon
och använda maskiner. Datum för senaste översyn av SPC 11/2014. För fullständig produktinformation, se www.fass.se
PHSWE/ZYT/0914/0007g(2)
ZYTIGA® (abirateronacetat)
Glasklart
NUF, June 3-5 2015
Address: Dockplatsen 1
Turning
Torso
N
Jörgen Kocksg
1
Carlsg
o
psbr
Skep
sg
arv
ra V
o
t
S
n
Malmö Central Station
2
Malmöhus slott
Malmöhus Castle
500 m
F
●
3
Stortorget
allg
N. V
Österg
F
●
4
Taxi Skåne, +46(0)40-330 330
Taxi 97, +46(0)40-97 97 97
Address: Malmö Arena
Hyllie Stationstorg 4
Rådhuset/Town Hall
Lilla torg
Slot
Baltzarsg
S. Nyg
Gustav Adolfs torg
F
●
8
ningg
Drott
Slottsparken
6
F
●
6
sg
tad
örs
S. F
Rådmansg
Station Triangeln
S:t Johannesgatan
F Flygbussar
Airport Coaches
Malmö airport
Ca
rl
Pildammsv
Buss/Bus nr 6
Triangeln-BorgmästaregårdenHyllie/Malmö Arena
Station
Triangeln
Smedjegatan
Joh
Södervärn
P
nE
ric
sso
Borgmästargården
6
F
●
Skånes Universitetssjukhus/
University
Hospital
S. Förstadsg
Buss/Bus nr 8
Gustav Adolfs torgHyllie/Malmö Arena
Gu
s
taf
sv
Pildammsparken
ns
v
Dalaplan
4 km
2014-11-17
➞
➞
Stadiong
Station Hyllie
g
irals
Am
Bergsg
7
H Hostel
8
F
●
sg
ning
Före
Triangeln
Train station
6
g
irals
Am
H
F
●
P
S. Förstadsg
Fersens v.
Stadsbiblioteket
1 Comfort Hotel
City Library
2 Elite Hotel Savoy
entsg
Regem
3 Elite Hotel Residens
4 Renaissance Hotel
5 BW Noble House
6 Scandic Malmö City
7 Scandic Triangeln
Malmö Opera
8 Malmö Arena Hotel
lv
Kungsparken
Gågata
Pedestrian street
No
be
tsg
5
4 km
Malmö Arena
8 Malmö Arena Hotel
©Destination Öresund
NUF 2015
We thank our exhibitors.
101. AbbVie AB
202. Adcare AB
100. Allergan Norden AB
321. American Medical Systems Sw.
204. Bactiguard AB
305. Bayer AB
105. BK Medical AB
106. BL Medical ApS
307. Boston Scientific Nordic AB
102. Coloplast AB / Urologi
103. Coloplast AB / Inkontinens
314. Cook Medical
301. Dolema AB
203. EDAP TMS GmbH
313. Evolan Pharma AB
303. EXINI Diagnostics AB
306. Ferring Läkemedel AB
208. Intuitive Surgical
205. Ipsen AB
207. Karl Storz Endoskop Sverige AB
302. Kebomed
309. KOELIS
315. Medac
318. MLS Medical AS
317. Normedi Nordic AS
201. Olympus Sverige AB
104. Pharmanovia A/S
312. Photocure ASA
308. Prostrakan
316. ProstaLund AB
320. Sandoz A/S
304. Sanofi AB
310. Sobi AB
319. Stryker
206. Wellspect HealthCare AB
311. Vingmed AB
POSTERS
321
319
320
318
316
317
315
Coffee / Lunch
314
313
312
311
308
310
307
309
306
NÖD
UTGÅNG
304
305
303
302
NÖD
UTGÅNG
BAR
NÖD
UTGÅNG
106
105
103
nch
205
ffee
/ Lu
104
102
204
Co
203
Arena
rummet
202
Janssen
Astellas
201
101
Arena
rummet
m
ESK
oo
INFOD
206
Co
208
207
ffee
/ Lu
nch
301
BAR
100
Coffee / Lunch
Cl
o
r
ak
Palissad
Speakers Service
Center
Planum Sponsor
Gold Sponsor
Congress secretariat
Destination Öresund AB
Fersens väg 18 • 211 42 Malmö, Sweden
Tel 040-300 665
lars@destinationoresund.com
Layout: Aletia Design
www.aletiadesign.com